This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
In the Views & Reviews article “l-Dopa in dystonia: A modern perspective,” Maas et al. provided a historical perspective on the statement “Every child exhibiting dystonia merits an l-dopa trial, lest the potentially treatable condition of dopa-responsive dystonia is missed,” and discussed the current diagnostic and therapeutic applications of l-dopa in neurologic practice, contrasted these with its approved indications, and shared their view on both a diagnostic and therapeutic trial in children and adults with dystonia. Commenting on the article, Dr. Coleman notes that 4 relevant articles from 1969 to 1974 were omitted in the historical background, including the first report of the dose level of l-dopa therapy in dystonia, the first double-blind study, the first report of side effects, and the first report of dopamine-B-hydroxylase levels. Maas et al., authors of the review, cite word limit restrictions as one of the reasons those articles were omitted.
In the Views & Reviews article “l-Dopa in dystonia: A modern perspective,” Maas et al. provided a historical perspective on the statement “Every child exhibiting dystonia merits an l-dopa trial, lest the potentially treatable condition of dopa-responsive dystonia is missed,” and discussed the current diagnostic and therapeutic applications of l-dopa in neurologic practice, contrasted these with its approved indications, and shared their view on both a diagnostic and therapeutic trial in children and adults with dystonia.
Footnotes
Author disclosures are available upon request (journal{at}neurology.org).
- Copyright © 2017 American Academy of Neurology
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
